| Document Date: 2012-08-14 09:32:56
Open Document File Size: 92,10 KBShare Result on Facebook
Company LFB BIOTECHNOLOGIES / LFB Group / Thallion Pharmaceuticals Inc. / / Continent Europe / / Country France / United States / / Currency EUR / / Event FDA Phase / / IndustryTerm biopharmaceutical / treatment of serious and often rare diseases / cancer therapy / plasma-derived medicinal products / dual antibody product / medicinal products / biotechnology company developing pharmaceutical products / / MedicalCondition often rare diseases / foodborne bacterial infections / Shiga toxin-producing E. coli bacterial infections / STEC infection / infection / infectious disease / STEC infections / / MedicalTreatment innovative therapies / anti-cancer therapy / intravenous infusion / / Person Guillaume Bologna / Allan Mandelzys / / Position Chief Executive Officer / Executive Vice-President for Development Programs / / Product TSX / Shigamabs / Shigamabs® / / Technology pharmacokinetics / antibodies / biotechnology / treating cancer / medicinal products / / URL www.thallion.com / /
SocialTag |
- PRESS RELEASE - Thallion and LFB complete patient enrollment of Phase II Shigatec trial Montréal, Les Ulis, January 9, 2012 – Thallion Pharmaceuticals Inc. (TSX: TLN) and LFB BIOTECHNOLOGIES announced today that th